Erenumab OverviewErenumab (trade name Aimovig) is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It was the first of the group of CGRPR antagonists to be approved in 2018. Contents 1 Medical uses 2 Side effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 History 5.1 Development 5.2 Approval and marketing 6 See also 7 References ...
Read more Erenumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Erenumab
Recent Erenumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 70mg/ml
Other drugs which contain Erenumab or a similar ingredient: (1 result)
- AIMOVIG Erenumab-aooe